{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:01:06Z","timestamp":1784930466456,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib have demonstrated encouraging activity in prolonging progression\u2010free survival (PFS) in several bone sarcoma entities in prospective clinical trials. This retrospective study aims to analyze the safety and efficacy of anlotinib, a novel multi\u2010target TKI, in patients with locally unresectable or metastatic bone sarcoma at three institutions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with advanced bone sarcoma administered anlotinib 12\u00a0mg once daily, 2\u00a0weeks on\/1\u00a0week off, from June 2018 to June 2020, until disease progression or intolerance of treatment. The primary endpoints were objective response rate (ORR) and PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010eight patients were analyzed: 27\u00a0have osteosarcoma, 9\u00a0have chondrosarcoma, 8\u00a0have Ewing's sarcoma, and 3\u00a0have chordoma. The median age was 24\u00a0years (range, 16\u201368\u00a0years), and the median number of prior regimens was 1 (range, 0\u20134). Until the final follow\u2010up, five patients obtained a partial response and while 24 achieved stable disease. The ORR in all patients was 10.4%, and the median PFS was 4.6\u00a0months, with a progression\u2010free rate (PFR) at 3\u00a0months and 6\u00a0months of 72.9% and 35.4%, respectively. The ORR and median PFS varied much among tumor subtypes. The most frequent grade 3\u20134 adverse events (AEs) were pneumothorax, hand\u2010foot syndrome, cholesterol elevation, hypertriglyceridemia, and fatigue. No patients died from anlotinib\u2010related AEs during the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Anlotinib may show promising antitumor activity in unresectable or metastatic bone sarcoma. The ORR and median PFS of anlotnib are similar to those of other targeted drugs in different subtypes of sarcomas. The AEs were generally mild and tolerated well. Further studies of anlotinib in selected subtypes of bone sarcoma are needed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4286","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T17:42:58Z","timestamp":1632678178000},"page":"7593-7600","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-7923","authenticated-orcid":false,"given":"Zhiyong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Henan Provincial People's Hospital and People's Hospital of Zhengzhou University Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Zhengzhou Orthopedics Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30466-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0397"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1743"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2028910"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70337-0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30589"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040506"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1503714"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr151"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30825-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5526"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32180"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010083"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0528"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3610"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.426"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0542"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr151"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30742-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.5381"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70286-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2359"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28845"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32515"},{"key":"e_1_2_9_27_1","unstructured":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=54232. Accessed September 12 2021."},{"key":"e_1_2_9_28_1","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03416517. Accessed September 12 2021."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4286","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:55:29Z","timestamp":1693212929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/cam4.4286"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4286","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,26]]},"assertion":[{"value":"2021-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}